AVZO-021

Phase 2Small molecule

AAvenzo Therapeutics, Inc.

AVZO-021 is one of 49 small molecule programs targeting HR+/HER2- Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HR+/HER2- Breast CancerRecruiting

Patients With Advanced Solid TumorsRecruiting

HR+/HER2- Breast CancerPreclinical

Recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

249 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

20 2

Eloxatin

Teva

Phase 2

9 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

23 4

Tecentriq

Roche

Phase 2

4 5

Camptosar

Pfizer

Phase 2

4 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

15 7

Erbitux

IImclone

Phase 2

10 8

Lazcluze

Johnson & Johnson

Phase 2

1 9

Tuoyi

CCoherus Oncology, Inc.

Phase 2

9 10

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT05867251

Q3 2030

PreclinicalRecruiting

HR+/HER2- Breast Cancer

NCT06998407

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Study of AVZO-021 in Patients With Advanced Solid Tumors

Recruiting·AAvenzo Therapeutics, Inc.·Phase 1/2·NCT05867251·430 enrolled

HR+/HER2- Breast Cancer1 trial

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in Patients With Advanced Solid Tumors

Recruiting·AAvenzo Therapeutics, Inc.·Preclinical·NCT06998407·380 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AVZO-021. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AVZO-021 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AVZO-021. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Avenzo Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAvenzo Therapeutics, Inc.

AVZO-021

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Q3 2030

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

HR+/HER2- Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News